Company / Cash & Equivalents
Seres Therapeutics, Inc. Cash & Equivalents History
FY2015-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$45.8M
FY2025
5-year range
$45.8M / $180.0M
FY2021-FY2025
Trend
-71.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 10 years, ranging from $2M in FY2015 to $180M in FY2021.
Based on SEC 10-K filings.
$46M in FY2025 with a 10-year CAGR of +39.4%.
Declined from $163M to $46M over the past 3 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -34.5%
- 5-Year CAGR
- -17.0%
- 10-Year CAGR
- +39.4%
Key checks
Key Insights
- 5-year CAGR of -17.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 71.9% year-over-year.
- Peak cash & equivalents was recorded in FY2021.
- Lowest cash & equivalents in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.18 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.8M | -71.9% |
| FY2023 | $163.0M | +0.0% |
| FY2022 | $163.0M | -9.4% |
| FY2021 | $180.0M | +55.1% |
| FY2020 | $116.0M | +78.2% |
| FY2019 | $65.1M | -24.1% |
| FY2018 | $85.8M | +16.1% |
| FY2017 | $73.9M | -35.3% |
| FY2016 | $114.2M | +6803.6% |
| FY2015 | $1.7M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 24, 2026